AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative and Chronic Spontaneous Urticaria
ByAinvest
Tuesday, Nov 11, 2025 2:09 am ET1min read
InflaRx N.V. reported positive Phase 2a data for INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). Efficacy data were reported from 29 of 31 HS patients and 30 of 31 CSU patients. The study showed rapid and consistent reductions in ANs and dTs, improvements in measures such as HiSCR, IHS4, NRS30, and DLQI. Safety data from 33 HS patients showed no signal of safety concern, with no serious adverse events reported. InflaRx believes these data provide strong rationale for further development in both indications.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet